PostScript

Relationship between asthma severity and progression of Alzheimer's disease

Severity of asthma is occasionally modulated by neuropsychiatric conditions.¹ However, little is known about the impact of cognitive decline on asthma severity. Cognitive decline is a core symptom in patients with Alzheimer's disease (AD).² AD is a disease characterised by progressive cholinergic failure³ that could possibly reduce airway hyperresponsiveness to cholinergic stimulation and thus symptoms of asthma. Furthermore, the functions of T lymphocytes—which play a crucial role in the development of chronic asthma—are partially impaired in patients with AD related diseases.⁴ We hypothesised that declining cognitive function might result in an improvement in asthma, and prospectively studied the contribution of the progression of AD to the clinical course of asthma.

Eight patients with asthma of mean (SE) duration 15.3 (0.9) years with concomitant AD were identified and prospectively followed for 5 years from 1995 to 2000. All subjects were treated with oral theophylline (200 mg twice daily) and a 200 µg dose of fenoterol given by a flow driven inhaler as needed. Family members of the patients completed a diary card that recorded asthma symptoms,⁵ use of daily medication, and the number of hospital admissions for asthma during the 5 years prior to study entry and the 5 year observation period. Cognitive function was assessed by Mini-Mental State Examination (MMSE)⁶ and sputum eosinophil counts⁷ and methacholine challenge tests⁸ were performed both at enrolment in the study and at the end. Informed consent was obtained from each patient, his or her family, and an attending physician.

MMSE scores were significantly decreased during the 5 year observation period in all subjects (table 1). Overall attack frequency and severity of asthma symptoms significantly decreased during the progression of cognitive impairment in all but one asthmatic subject with AD (table 1). Induced sputum obtained at the end of the study from seven subjects with improved asthma had a significantly lower percentage of eosinophils than at the start of the study (2.2 (0.4)% at end point

v 10.7 (2.8)% at baseline, n=7, p=0.008), but there were no significant differences in the mean percentages of macrophages, neutrophils, or lymphocytes. By contrast, in all subjects the minimum cumulative dose of methacholine that induced an increase in respiratory resistance at the end of the study was not significantly different from that obtained at study enrolment (0.426 (0.252) U at end point v 0.368 (0.144) U at enrolment in the study, n=8, p=0.26). No other precipitating factors for asthma were identified during the study period in any subject.

Both overall attack frequency and severity of asthma symptoms decreased significantly during the progression of cognitive impairment in asthma patients with AD. However, peripheral cholinergic function might not be impaired in the airway in patients with AD despite an extensive loss of central cholinergic neurons.³ It has been reported that the nervous system may modulate immunological and inflammatory responses.⁹ Our results suggest that progression of AD might provide an ameliorating effect on the clinical course of asthma, probably due to alterations in the immunological responses including eosinophilic inflammation in the airway.

T Ohru, H Arai, M Ichinose, T Matsui, M Yamaya, H Sasaki

Department of Geriatric and Respiratory Medicine, Tohoku University School of Medicine, Sendai 980-8574, Japan

Correspondence to: Dr H Sasaki, Department of Geriatric and Respiratory Medicine, Tohoku University School of Medicine, 1-1 Seiryomachi, Aoba-ku, Sendai 980-8574, Japan; dept@geriat.med.tohoku.ac.jp

References

- Campbell DA, Yellowlees PM, McLennan G, *et al*. Psychiatric and medical features of near fatal asthma. *Thorax* 1995;**50**:254-9.
- McKhaan G, Drachman D, Folstein M, *et al*. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA work group under auspices of the Department of Health and Human Services Task Force on Alzheimer's disease. *Neurology* 1984;**34**:939-44.
- Davis KL, Mohs RC, Martin D, *et al*. Cholinergic markers in elderly patients with early signs of Alzheimer's disease. *JAMA* 1999;**281**:1401-6.

If you have a burning desire to respond to a paper published in *Thorax*, why not make use of our "rapid response" option? Log on to our website (www.thoraxjnl.com), find the paper that interests you, and send your response via email by clicking on the "eLetters" option in the box at the top right hand corner.

Providing it isn't libellous or obscene, it will be posted within seven days. You can retrieve it by clicking on "read eLetters" on our homepage.

The editors will decide as before whether to also publish it in a future paper issue.

- Park E, Alberti J, Mehta P, *et al*. Partial impairment of immune functions in peripheral blood leukocytes from aged men with Down's syndrome. *Clin Immunol* 2000;**95**:62-9.
- Nakasato H, Ohru T, Sekizawa K, *et al*. Prevention of severe premenstrual asthma attacks by leukotriene receptor antagonist. *J Allergy Clin Immunol* 1999;**104**:585-8.
- Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State": a practical method for grading the cognitive state of patients for clinicians. *J Psychiatr Res* 1975;**12**:189-98.
- Fahy JV, Liu J, Wong H, *et al*. Cellular and biochemical analysis of induced sputum from asthmatic and from healthy subjects. *Am Rev Respir Dis* 1993;**147**:1126-31.
- Takishima T, Hida W, Sasaki H, *et al*. Direct-writing recorder of the dose-response curves of the airway to methacholine. *Chest* 1981;**80**:600-6.
- Shalit F, Sredni B, Brodie C, *et al*. T lymphocyte subpopulations and activation markers correlate with severity of Alzheimer's disease. *Clin Immunol Immunopathol* 1995;**75**:246-50.

IL-1 haplotypes and lung function decline

We read with interest the paper by Joos *et al*¹ on the association of IL-1 gene haplotypes with decline in lung function in smokers and share their view on a possible role of IL-1 genetics in inflammatory respiratory diseases. We have analysed the same polymorphism by

Table 1 Assessment of asthma severity and change in cognitive function at study entry (baseline) and 5 year follow up (end point) in asthma patients with Alzheimer's disease

Case	Age (y)	Sex	MMSE score		Asthma symptom score		Daily inhaler puffs		Number of hospital admissions for asthma	
			Baseline	End point	Baseline	End point	Baseline	End point	Baseline	End point
1	67	M	23	18	6.4	1.2	1.3	0	2	0
2	66	M	21	16	8.6	2.2	1.4	0	2	0
3	70	F	23	17	10.2	1.6	2.4	0	3	1
4	65	M	22	15	7.8	1.2	2.6	1.4	3	0
5	65	F	21	16	7.5	0.4	3.3	1	2	0
6	69	F	23	17	9.4	3.6	1.9	0.4	3	0
7	66	F	22	16	9.2	2.4	2.2	0	2	0
8	68	M	23	21	7.6	7.4	2.8	2.6	3	2
Mean (SE)	67.0 (0.7)		22.3 (0.3)	17.0 (0.7)*	8.4 (0.5)	1.8 (0.4)†	2.2 (0.3)	0.4 (0.2)‡	2.4 (0.2)	0.1 (0.1)§

MMSE=Mini-Mental State Examination; SE=standard error.

*p<0.0001 (Wilcoxon rank test) compared with baseline data in all asthma patients with Alzheimer's disease; †p<0.0001; ‡p=0.0001; §p<0.0001 compared with baseline data in seven asthma patients with Alzheimer's disease (cases 1-7).

Table 1 Decline in FEV₁ (ml/year) in non-smoking asthmatics and controls in different putative IL-1 haplotypes

IL-1 haplotype	(1) IL1RN A2/ IL1B -511T	(2) IL1RN A2/ IL1B -511C	(3) IL1RN A1/ IL1B -511T	(4) IL1RN A1/ IL1B -511C	p value*	Post hoc tests between allele groups†
Non-smoking controls (n=124)	41.8 (13.8) (n=54)	44.8 (12.3) (n=32)	50.7 (11.2) (n=7)	45.5 (19.4) (n=31)	0.27	Not tested
Non-smoking new asthma cases (n=40)	63.2 (24.6) (n=18)	37.7 (20.7) (n=4)	30.9 (16.9) (n=4)	51.0 (24.8) (n=14)	0.0443	3<1, p=0.02 2<1, p=0.06

*Two way analysis of variance; †LSD test of means.

the same methods in adult incident non-smoking asthmatic patients and non-smoking controls. Our results indicate that the association of IL-1 genetics with rate of decline in lung function is not limited to smokers.

New adult asthma cases and controls were selected from a cohort of the Mini-Finland Health Survey (MFHS) and later re-evaluated. A more detailed description of the methods used in MFHS has been published elsewhere.² The accuracy of the method of asthma case ascertainment has also recently been described.³ IL-1 haplotypes were found to be significantly associated with the rate of decline of lung function in non-smoking incident cases of asthma (new asthma during follow up) but not in controls (table 1). Of the individual haplotypes, Joos *et al* found that *IL1RN A1/IL1B -511T* was associated with a rapid decline of lung function in smokers and *IL1RN A2/IL1B -511T* with a slow decline. In our control group the observed differences were not significant. Surprisingly, in the asthma group the haplotypes had the opposite effects from those in smokers: *IL1RN A1/IL1B -511T* was associated with a slower decline in lung function and *IL1RN A2/IL1B -511T* with a more rapid decline. *IL1RN A2/IL1B -511T* has previously been found to be associated with many inflammatory diseases.⁴ The function of these haplotypes would therefore appear to be disease specific.

J Karjalainen

Tampere University Hospital, Department of Respiratory Medicine and Medical School, FIN-33014 University of Tampere, Finland; jussi.karjalainen@uta.fi

J Hukkonen, M Hurme

Tampere University Hospital, Centre for Laboratory Medicine and Department of Microbiology and Immunology

References

- Joos L, McIntyre L, Ruan J, *et al*. Association of IL-1β and IL-1 receptor antagonist haplotypes with rate of decline in lung function in smokers. *Thorax* 2001;56:863–6.
- Von Hertzen L, Reunanen A, Impivaara O, *et al*. Airway obstruction in relation to symptoms in chronic respiratory disease: a nationally representative population study. *Respir Med* 2000;94:356–63.
- Karjalainen A, Kurppa K, Martikainen R, *et al*. Work is related to a substantial portion of adult-onset asthma incidence in the Finnish population. *Am J Respir Crit Care Med* 2001;164:565–8.
- Hurme M, Lahdenpohja N, Santtila S. Gene polymorphisms of interleukins 1 and 10 in infectious and autoimmune diseases. *Ann Med* 1998;30:469–73.

Authors' reply

Karjalainen and colleagues present interesting data on the relationship of IL-1β and IL-1 receptor antagonist haplotypes and the rate of decline of lung function in incident asthmatic subjects in a Finnish cohort. We reported that

the *IL1RN A1/IL1B -511T* haplotype was associated with a more rapid decline in lung function in smokers in the Lung Health Study; in contrast, they found that this same haplotype was associated with a slower rate of decline in lung function in patients with asthma. The authors suggest that this apparent contradiction may be because the function of these haplotypes is disease specific. We agree that a different effect of the same haplotype could occur because of fundamental differences in the pathophysiological processes which cause airflow obstruction in asthma and chronic obstructive pulmonary disease (COPD). In asthma, CD4+ Th2 cells underlie persistent eosinophilic inflammation and remodelling in medium sized and larger airways. In COPD, neutrophils and CD8+ cells appear to play an important role in the airflow limitation by causing proteolytic destruction of peripheral lung parenchyma and fibrous scarring of the small membranous and respiratory bronchioles. Although inflammation appears to be central to both processes, the roles of IL-1β and of IL-1 receptor antagonist in these conditions is unknown and it is possible that the polymorphisms that are responsible for this haplotype could have opposite effects.

Alternatively, these apparently contradictory results could be due to different genetic histories of the two study groups. Our study group was taken from the white population in the United States whereas Karjalainen *et al* studied Finnish individuals. It may be that the polymorphisms which are typed to establish these haplotypes do not, by themselves, change the function or level of expression of the IL proteins but are in linkage disequilibrium with a causal polymorphism(s). In this case, the IL1 allelic associations could be different in different populations. The bottleneck in the genetic history of the Finnish people could have established a founder effect and resulted in the function altering allele being found on a different genetic background from that in the white population of the United States.

Whatever the correct explanation, these results support the growing evidence that

genetic variation at the IL-1 locus is important in modulating the severity and/or functional consequences of a number of inflammatory conditions.

L Joos, P D Paré, A Sandford

UBC McDonald Research Laboratories and iCAPTURE Center, St Paul's Hospital, University of British Columbia, Vancouver, BC V6Z 1Y6, Canada; asandford@mrl.ubc.ca

Molecular analysis of drug resistant TB

Since the mid 1980s the number of notified cases of TB in the UK has continued to rise with the largest increases noted in London and inner city areas.¹ King George Hospital in Goodmayes, Essex provides clinical services to a population of approximately 230 000; 17% are non-white subjects including immigrants from countries with high rates of *M tuberculosis* infection and drug resistance. From September 1996 to July 1997 47 adult cases of culture proven TB were identified including seven with drug resistant isolates. None was identified by contact tracing. A previous TB audit of African born patients revealed a high rate of drug resistance (6/24 (25%)) and delays in obtaining drug sensitivities which could have been detrimental to patient management.²

Under these circumstances the rapid identification of drug resistance in *M tuberculosis* isolates would have been helpful. The aim of this study was to determine retrospectively the usefulness of PCR-reverse hybridisation methods for screening for mutations within or adjacent to *M tuberculosis* genes associated with rifampicin (*rpoB*) and isoniazid (*inhA*, *katG*, and *ahpC*) resistance. We also determined whether resistance genotyping combined with IS6110 typing could help to identify clusters of drug resistant cases not previously identified by contact tracing.

Seven consecutive drug resistant *M tuberculosis* culture isolates were analysed for rifampicin and isoniazid resistance and the results were compared with conventional susceptibility testing. The commercially available

Table 1 Demographic data, site, phenotypic and genotypic resistance of the seven resistant study isolates

Isolate	Age	Country of birth	Site of TB	Drug resistance	Resistance genotype	
					Isoniazid	Rifampicin
1	24	Nigeria	Pulmonary	INH/RIF	Wild type	<i>rpoB</i> mutation
2	21	Somalia	Pulmonary	INH	<i>katG</i> mutation	Wild type
3	40	Zaire	Pulmonary	INH	<i>inhA</i> mutation	Wild type
4	17	Zaire	Pulmonary	INH	<i>inhA</i> mutation	Wild type
5	20	Zaire	Pulmonary	INH	<i>inhA</i> mutation	Wild type
6	42	UK	Pulmonary	INH	<i>inhA</i> mutation	Wild type
7	44	Somalia	Sternum	PZ	Wild type	Wild type

INH=isoniazid; RIF=rifampicin; PZ=pyrazinamide. Isolates 3 and 5 had indistinguishable IS6110 types. Isolates 1 and 4 were not typable due to insufficient culture and the banding pattern of isolate 6 was uninterpretable.

assay INNO-LiPA Rif.TB³ was used to detect *rpoB* mutations and an in-house PCR-reverse hybridisation line probe was used to detect mutations in or adjacent to the *katG*, *inhA*, and *ahpC* genes.⁴ The isolates were also IS6110 typed.⁵

The single rifampicin and isoniazid resistant isolate had an *rpoB* gene mutation associated with rifampicin resistance (table 1). Four of the five isoniazid resistant isolates had the same single point mutation upstream of the *inhA* gene and the other a single *katG* point mutation. Isolates 3 and 5 had indistinguishable IS6110 types that could represent isolates where recent transmission had occurred. No mutations were detected in the 40 fully susceptible isolates.

PCR-reverse hybridisation methods were highly sensitive and specific at detecting mutations that predict for isoniazid and rifampicin resistance. We also demonstrated that different point mutations can be used to discriminate between isoniazid resistant isolates. We believe that with automation and the addition of oligonucleotide probes designed to detect mutations associated with pyrazinamide (*pncA*)⁶ and ethambutol (*embB*)⁷ resistance, a system capable of detecting resistance to four front line antituberculous drugs will soon be commercially available. Rapid resistance detection by PCR-reverse hybridisation is likely to have a major impact on patient management and our understanding of the epidemiology of drug resistant TB.

Acknowledgements

We would like to thank the Steering Group Members of the "Molecular Epidemiology of Tuberculosis in London" for allowing us access to their *M tuberculosis* IS6110 type database and to the Mycobacterial Reference Laboratory (Dulwich) for conventional susceptibility testing.

M Melzer, T J Brown, G L French

Department of Infection, St Thomas' Hospital, London SE1 7EH, UK

A Dickens, T D McHugh

Department of Medical Microbiology, Royal Free and University College Medical School, London NW3 2PF, UK

L R Bagg, R A Storrington, S Lacey

King George Hospital, Goodmayes, Essex IG3 8YB, UK

Correspondence to: Dr M Melzer, Department of Infection, St Thomas' Hospital, London SE1 7EH, UK; markmelzer@hotmail.com

References

- 1 **Pearson AD**, Hamilton GR, Healing TD, *et al*. Summary of a report of the working party on tuberculosis of the London group of Consultants in Communicable Disease Control. *J Hosp Infect* 1996;**33**:165-79.
- 2 **Melzer M**, Storrington RA, Lacey S, *et al*. Tuberculosis in African born adults: can we improve clinical practice? *J R Coll Physicians* 1998;**32**: 493-4.
- 3 **Cooksey RC**, Morlock GP, Glickman S, *et al*. Evaluation of a line probe assay kit for characterization of *rpoB* mutations in rifampicin-resistant *Mycobacterium tuberculosis* isolates from New York City. *J Clin Microbiol* 1997;**35**:1281-3.
- 4 **Brown TJ**, French GL. Genotypes associated with isoniazid resistance in *Mycobacterium tuberculosis* isolates seen at a London teaching hospital. *J Microbiol Methods* 1999;**38**:226.
- 5 **van Embden JDA**, Cave MD, Crawford JT, *et al*. Strain identification of *Mycobacterium tuberculosis* by DNA fingerprinting: recommendations for a standardised methodology. *J Clin Microbiol* 1993;**31**:406-9.

- 6 **Hirano K**, Takahashi M, Kazumi Y, *et al*. Mutations in *pncA* is a major mechanism of pyrazinamide resistance in *Mycobacterium tuberculosis*. *Tuberc Lung Dis* 1998;**78**:117-22.
- 7 **Sreevatsan S**, Stockbauer KE, Pan X, *et al*. Ethambutol resistance in *Mycobacterium tuberculosis*: critical role of *embB* mutations. *Antimicrob Agents Chemother* 1997;**41**:1677-81.

Lung bullae and marijuana

A previous paper from this hospital described apical lung bullae in four young male marijuana smokers, three West Indian and one Caucasian.¹ Two further cases were recently reported, both in Caucasian men.² We describe three further cases (one woman) with large upper lobe bullae. All are Caucasian and had a prolonged history of heavy marijuana smoking with an alpha₁-antitrypsin level within the normal range (table). These further cases support the view that marijuana may have a causal role in the development of lung bullae. We suggest that a detailed marijuana smoking history is taken from patients of all ethnic origins with upper lobe bullae.

C S Thompson, R J White

Department of General Medicine, Frenchay Hospital, Bristol BS16 1LE, UK

Correspondence to: Dr C S Thompson, Department of General Medicine, Frenchay Hospital, Bristol BS16 1LE, UK.

References

- 1 **Johnson MK**, Smith RP, Morrison D, *et al*. Large lung bullae in marijuana smokers. *Thorax* 2000;**55**:340-2.
- 2 **Rawlins R**, Carr CS, Brown KM, *et al*. Minerva. *BMJ* 2001;**323**:1012.

Pathophysiology of COPD

The paper by Dentener *et al*¹ is interesting and contributes to the understanding of the pathophysiology of chronic obstructive pulmonary disease (COPD). It is becoming clear that COPD is a systemic syndrome, and this paper suggests some potential mechanisms. However, a number of issues merit further comment.

It is noted that, in healthy controls, there is a wide range of C reactive protein (CRP) values extending well beyond what would be considered to be the normal range. The reason for this is unclear, but it does suggest that these individuals are not as healthy as

described. In addition, patients with stable COPD have a range of CRP values that also extend beyond this normal range. This is not consistent with previous studies, which suggests that, in patients with stable COPD, the range of CRP values falls within the normal range.² Although patients with bronchiectasis were excluded, it is possible that undiagnosed bronchiectasis may have been present. Previous work has shown that 29% of patients presenting with what appeared to be stable COPD had CT evidence of at least mild bronchiectasis.³ This could conceivably explain a wider range of CRP levels. In addition, it is interesting that after just 5 days of treatment for an acute exacerbation of COPD the CRP had returned to a level below that of the stable cohort in the study. Since standard treatment for an exacerbation is able to achieve this in just a few days, it suggests that the stable group may have contained individuals that were in fact not so stable.

The authors allude to the potential confounding effect of systemic corticosteroids in the study. The changes in total leucocyte count during the exacerbation are likely to be due to the effect of prednisolone, making it difficult to interpret the changes in leucocyte count. In stable patients the action of corticosteroids may also confound the results. It is possible that, even in patients using inhaled corticosteroids, leucocyte numbers could be affected since there may be significant bioavailability at higher doses. Leucocyte count should therefore not be used as a marker for systemic inflammation in these patients.

Finally, it would appear that the exacerbations of COPD might have been mild, despite the presence of severe COPD on lung function criteria. Although Paco₂ was slightly higher and Pao₂ slightly lower than in the stable group, these differences were small in magnitude. The pH was not significantly different and, in fact, the stable group contained individuals with a lower pH (range 7.30-7.50) than in the exacerbated group (pH 7.34-7.49). Although the mean CRP level appears higher than in stable patients, the range does not differ significantly. This may therefore have led to a less profound change in inflammatory markers than might have been expected, and a study looking at more severe exacerbations may be more revealing.

M Kelly

Department of Respiratory Medicine, Belfast City Hospital, Belfast BT9 7AB, UK; m.g.kelly@qub.ac.uk

Table Characteristics at presentation of three cases of apical lung bullae in marijuana smokers

	Case 1	Case 2	Case 3
Age on presentation (years)	33	45	38
Sex	Male	Female	Male
Ethnic origin	Caucasian	Caucasian	Caucasian
Tobacco smoking history	9 pack years	10 pack years	20 pack years
Marijuana smoking history	2-3 joints/day, "heavy" 10 years	Weekends/evenings, "moderate" 10 years	0.25 oz marijuana/week, "heavy" 24 years
Alpha ₁ -antitrypsin (g/l) (normal range 1.1-2.1)	1.4	2.3	1.6
FEV ₁ (l) (% predicted)	2.7 (64)	2.4 (96)	3.7 (90)
FVC (l) (% predicted)	4.3 (85)	3.3 (112)	4.7 (94)
FEV ₁ /FVC (%)	63	73	79
Tico (% predicted)	9.44 (81)	4.99 (62)	-
Kco (% predicted)	1.44 (88)	1.10 (64)	-

FEV₁=forced expiratory volume in 1 second; FVC=forced vital capacity; Tico=carbon monoxide transfer factor; Kco=carbon monoxide transfer coefficient.

References

- 1 Dentener MA, Creutzberg EC, Schols AMWJ, *et al.* Systemic anti-inflammatory mediators in COPD: increase in soluble interleukin 1 receptor II during treatment of exacerbations. *Thorax* 2001;**56**:721–6.
- 2 Gompertz S, Bayley DL, Hill SL, *et al.* Relationship between airway inflammation and the frequency of exacerbations in patients with smoking related COPD. *Thorax* 2001;**56**:36–41.
- 3 O'Brien C, Guest PJ, Hill SL, *et al.* Physiological and radiological characterisation of patients diagnosed with chronic obstructive pulmonary disease in primary care. *Thorax* 2000;**55**:635–42.

Authors' reply

Dr Kelly has some concerns about the levels of C reactive protein (CRP) in the healthy controls and patients with clinically stable COPD in our study. The control group used consisted of randomly selected subjects over 50 years of age and living in the same area as the patients. These subjects had no evidence of COPD based on questionnaires and lung function testing, did not exhibit any acute or chronic disease, and were not taking medication. Based on these selection criteria, this group was considered a healthy population control group. Although two of the 23 control subjects had enhanced CRP levels, the reason for which is unknown, they were not excluded in order to prevent bias. Non-parametric tests were used to compare the CRP levels between controls and COPD patients, and therefore the results are not affected by these two outliers.

Concerning the diagnosis of COPD, all patients in our study underwent high resolution computed tomographic scanning to exclude the presence of bronchiectasis.

There is increasing evidence that COPD is characterised by systemic effects which, among other factors, are reflected by enhanced circulating levels of inflammatory mediators in the circulation.¹ In line with the observations of increased levels of the acute phase proteins CRP and lipopolysaccharide binding protein (LBP) in patients in a clinically stable condition in this study and in previous studies by our group,² an association between increased plasma levels of the acute phase protein fibrinogen with reduced lung function and increased risk of COPD has recently been reported.³ Yasuda *et al* also reported enhanced CRP levels in patients with stable COPD.⁴ It should be noted from these studies^{2–4} that only part of the patient population exhibited enhanced acute phase protein levels, as was also the case in our study. This indicates that, although all patients were in a clinically stable condition, subgroups can be discriminated based upon inflammatory characteristics. This could be a factor contributing

to the discrepancy between the studies by Gompertz *et al*² and ours. No relationship was observed between CRP level and severity of disease,⁴ whereas separation of patients into normometabolic and hypermetabolic subgroups revealed enhanced levels of CRP in the latter group.² Further research is needed to elucidate the cause for the production of these acute phase proteins in subgroups of clinically stable COPD patients and its involvement in the pathogenesis of the disease. It is of interest to note that, although only some of the clinically stable patients had enhanced CRP levels, almost all patients who had an exacerbation of disease had increased CRP levels on day 1 of the exacerbation which declined during treatment.

We agree with Dr Kelly that treatment with corticosteroids could affect the leucocyte count in patients with clinically stable COPD. As reported in our paper, increased circulating levels of leucocytes were observed in the subgroup of clinically stable COPD patients treated with oral corticosteroids compared with those who did not receive oral corticosteroids. However, comparison of subgroups of patients without corticosteroid treatment (oral or inhaled or both) with control subjects still revealed significantly increased leucocyte counts (data not shown). This indicates that the enhanced levels of circulating leucocytes are not solely due to corticosteroid use, and could be a marker of the systemic inflammatory process in COPD. In line with this hypothesis, Noguera *et al* reported enhanced circulating levels of polymorphonuclear cells in patients with stable COPD, none of whom had received steroids before the start of the study (oral or inhaled).⁶

As discussed in our paper, administration of prednisolone during treatment of an exacerbation is most probably the cause for the observed rise in leucocyte counts. In order to determine the effect of an exacerbation on leucocyte counts, studies are currently being performed in our hospital in which blood from patients with an exacerbation is collected before the start of treatment.

COPD comprises a heterogeneous group of conditions characterised by chronic airflow limitation and destruction of lung parenchyma with clinical manifestations of dyspnoea, cough, sputum production, and impaired exercise tolerance. The definition of an acute exacerbation of COPD is still imprecise, and is generally based on varying combinations of symptoms. Rodriguez-Roisin *et al* suggested staging COPD exacerbations based on use of health care.⁷ They defined three levels of severity: mild, moderate and severe. During a mild exacerbation the patient has an increased need for medication which he/she can manage in their own environment; patients with a moderate exacerbation have

an increased need for medication and need to seek additional medical assistance; the patient with a severe exacerbation recognises obvious and/or rapid deterioration in his/her condition requiring admission to hospital. Based on this definition, the patients included in our study were suffering from severe exacerbations of disease. Only limited information is so far available concerning (changes of) inflammatory markers during exacerbations.

In our study the kinetics of pro- and anti-inflammatory markers have been analysed in patients with COPD during the first 7 days in hospital for an exacerbation of the disease. The results showed a significant decline in systemic levels of both CRP (at day 3) and LBP (at day 7) compared with day 1, whereas levels of the anti-inflammatory mediator soluble IL-1 receptor II dramatically increased (until day 5). This change in levels of inflammatory mediators may contribute to the clinical improvement of the patients. Additional studies are required to obtain more insight into the role of the inflammatory processes in the pathogenesis of exacerbations which could contribute to measurable parameters, in order to define the severity or outcome of disease more accurately.

M A Dentener, E C Creutzberg,
E F M Wouters

Department of Pulmonology, Maastricht University,
Nutrition and Toxicology Research Institute
Maastricht (Nutrim), Maastricht, The Netherlands;
Mieke.Dentener@pul.unimaas.nl

References

- 1 Barnes PJ. Medical progress: chronic obstructive pulmonary disease. *N Engl J Med* 2000;**343**:269–80.
- 2 Schols AM, Buurman WA, Staal van den Brekel AJ, *et al.* Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease. *Thorax* 1996;**51**:819–24.
- 3 Dahl M, Tybjaerg-hansen A, Vestø J, *et al.* Elevated plasma fibrinogen associated with reduced pulmonary function and increased risk of chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2001;**164**:1008–11.
- 4 Yasuda N, Gotoh K, Minatoguchi S, *et al.* An increase of soluble Fas, an inhibitor of apoptosis, associated with progression of COPD. *Respir Med* 1998;**92**:993–9.
- 5 Gompertz S, Bayley DL, Hill SL, *et al.* Relationship between airway inflammation and the frequency of exacerbations in patients with smoking related COPD. *Thorax* 2001;**56**:36–41.
- 6 Noguera A, Busquets X, Sauleda J, *et al.* Expression of adhesion molecules and G proteins in circulating neutrophils in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 1998;**158**:1664–8.
- 7 Rodriguez Roisin R. Toward a consensus definition for COPD exacerbations. *Chest* 2000;**117**(suppl 2):398–410s.